| http://www.w3.org/ns/prov#value | - ing Authorization Application in the EU for the commercialization of Omidria, Omeros' unproven preclinical and clinical development activities, regulatory oversight, product commercialization, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading Risk Factors" in the Company's Annual Report on Form 10-K filed
|
